About Us
Company
Contact Us
Technology
Pipeline
News
Events
Press Releases
Publications
Join Us
中文
Company
Technology
Pipeline
News
Publications
Join Us
Contact Us
News Center
Home
News
Doer Biologics' Globally First-in-Class Drug DR10624 Phase II Clinical Data Presented in Opening Session at AHA 2025
2025/11/11
Read more
Blockbuster | Up to 75% Reduction in Triglycerides, Up to 67% Reduction in Liver Fat: Doer Bio's DR10624 Phase 2 Clinical Results Shine in Opening Session at AHA 2025
2025/11/11
Read more
Preview | To Kick Off the Conference!Huadong Medicine’s Subsidiary Doer Bio's DR10624 Phase 2 Results for Severe Hypertriglyceridemia Selected as AHA 2025 Late-Breaker and Featured as Opening Presentation
2025/09/16
Read more
Doer Biologics Completes First Patient Dosing in Phase II Clinical Trial of DR10624 for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) / Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2025/04/22
Read more
Doer Biologics Announced Completes Enrollment of the Phase 2 Clinical Study of DR10624, reported by mainstream media
2025/03/12
Read more
Doer Biologics Completes Patient Enrollment in Phase II Clinical Study of DR10624 for Severe Hypertriglyceridemia
2025/03/10
Read more
Doer Biologics Announced First Patient Dosed in Phase 2 Study of DR10624, reported by mainstream media
2024/10/09
Read more
World's First Triple Agonist DR10624 Completes Full Enrollment in Phase 1b/2a Clinical Trial for Obesity with Hypertriglyceridemia
2024/07/09
Read more
Zhejiang Doer Biologics Announces License Agreement with BioNTech
2023/07/11
Read more
Many mainstream media reported the collaboration between Zhejiang Doer Biologics and MSD
2022/12/19
Read more
Prev
1
2
3
4
Next
